AB1598P
Anti-Vesicular Monoamine Transporter 2 Antibody
Chemicon®, from rabbit
Synonym(s):
VMAT2
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
rat
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
immunohistochemistry: suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... SLC18A2(6571)
Specificity
Recognizes Vesicular Monoamine Transporter 2 (VMAT2). An antibody made to the C-terminal VMAT2 peptide detected a major band at ~55 kDa in postnuclear supernatants of CHO transfected with VMAT2 and not in wild type cells (Peter et al. 1995; Nirenberg et al. 1995). Some additional bands, both higher and lower molecular weight, were also detected and remain unaffected by the inclusion of protease inhibitors. Higher molecular weight bands may represent glycosylated VMAT2 (Peter et al. 1995; Nirenberg et al. 1995, Liu et al. 1994). VMAT2 has been localized in adrenal chromaffin cells, sympathetic ganglion cells, enterochromaffin-like cells of the stomach and in CNS (Peter et al. 1995; Nirenberg et al. 1995; Nirenberg et al. 1996). May recognize human due to the 92% homology between rat and human VMAT2.
Immunogen
A 13 amino acid C-terminal peptide sequence from rat VMAT2 (Liu et al. 1992). This peptide is predicted to be cytoplasmic.
Application
Anti-Vesicular Monoamine Transporter 2 Antibody is an antibody against Vesicular Monoamine Transporter 2 for use in ELISA, IH & WB.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Ion Channels & Transporters
Ion Channels & Transporters
Western blot: 1-10 μg/mL (Chemiluminescence technique)
Immunohistochemistry: 1-20 μg/mL on paraformaldehyde fixed sections.
ELISA: 0.5-1.0 μg/mL (1 μg/mL VMAT1 peptide (Catalog Number AG251)/well)
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 1-20 μg/mL on paraformaldehyde fixed sections.
ELISA: 0.5-1.0 μg/mL (1 μg/mL VMAT1 peptide (Catalog Number AG251)/well)
Optimal working dilutions must be determined by end user.
Target description
55 kDa
Physical form
ImmunoAffinity Purified
Liquid in PBS with 0.1% BSA.
Storage and Stability
Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Analysis Note
Control
Rat brain tissue
Rat brain tissue
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ioannis Kourtesis et al.
ASN neuro, 7(5) (2015-10-31)
The spontaneously hypertensive rat (SHR) replicates many clinically relevant features of human essential hypertension and also exhibits behavioral symptoms of attention-deficit/hyperactivity disorder and dementia. The SHR phenotype is highly complex and cannot be explained by a single genetic or physiological
Rodolfo Gonzalez et al.
Cell transplantation, 24(4), 681-690 (2015-04-04)
Recent studies indicate that human pluripotent stem cell (PSC)-based therapies hold great promise in Parkinson's disease (PD). Clinical studies have shown that grafted fetal neural tissue can achieve considerable biochemical and clinical improvements in PD. However, the source of fetal
Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies.
Tong, J; Boileau, I; Furukawa, Y; Chang, LJ; Wilson, AA; Houle, S; Kish, SJ
Journal of Cerebral Blood Flow and Metabolism null
Jeffery C Sobieraj et al.
Brain structure & function, 221(1), 261-276 (2014-10-03)
Exercise (physical activity) has been proposed as a treatment for drug addiction. In rodents, voluntary wheel running reduces cocaine and nicotine seeking during extinction, and reinstatement of cocaine seeking triggered by drug-cues. The purpose of this study was to examine
Francesco Della Valle et al.
Stem cell reports, 14(1), 60-74 (2020-01-07)
In mammals, LINE-1 (L1) retrotransposons constitute between 15% and 20% of the genome. Although only a few copies have retained the ability to retrotranspose, evidence in brain and differentiating pluripotent cells indicates that L1 retrotransposition occurs and creates mosaics in
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service